Liesbeth Lenaerts, Huiwen Che, Nathalie Brison, Maria Neofytou, Tatjana Jatsenko, Hanne Lefrère, Charlotte Maggen, Darine Villela, Magali Verheecke, Luc Dehaspe, Anca Croitor, Sigrid Hatse, Hans Wildiers, Patrick Neven, Vincent Vandecaveye, Giuseppe Floris, Joris Robert Vermeesch, Frédéric Amant
BACKGROUND: Numerous publications have reported the incidental detection of occult malignancies upon routine noninvasive prenatal testing (NIPT). However, these studies were not designed to evaluate the NIPT performance for cancer detection. METHODS: We investigated the sensitivity of a genome-wide NIPT pipeline, called GIPSeq, for detecting cancer-specific copy number alterations (CNAs) in plasma tumor DNA (ctDNA) of patients with breast cancer. To assess whether a pregnancy itself, with fetal cell-free DNA (cfDNA) in the maternal circulation, might influence the detection of ctDNA, results were compared in pregnant (n = 25) and nonpregnant (n = 25) cancer patients...
November 1, 2020: Clinical Chemistry